BACKGROUND AND PURPOSE: Transoral laser microsurgery (TLM) and adjuvant radiotherapy are an established therapy regimen for locally advanced laryngeal cancer at our institution. Aim of the present study was to assess value of quality of life (QoL) data with special regard to organ function under consideration of treatment efficacy in patients with locally advanced laryngeal cancer treated with larynx-preserving TLM and adjuvant radiotherapy. PATIENTS AND METHODS: From 1994 to 2006, 39 patients (ten UICC stage III, 29 UICC stage IVA/B) with locally advanced laryngeal carcinomas were treated with TLM and adjuvant radiotherapy. Data concerning treatment efficacy, QoL (using the VHI [Voice Handicap Index], the EORTC QLQ-C30 and QLQ-H&N35 questionnaires) and organ function (respiration, deglutition, voice quality) were obtained for ten patients still alive after long-term follow-up. Correlations were determined using the Spearman rank test. RESULTS: After a median follow-up of 80.8 months, the 5-year overall survival rate was 46.8% and the locoregional control rate 76.5%, respectively. The larynx preservation rate was 89.7% for all patients and 100% for patients still alive after follow-up. Despite some verifiable problems in respiration, speech and swallowing, patients showed a subjectively good QoL. CONCLUSION: TLM and adjuvant radiotherapy is a curative option for patients with locally advanced laryngeal cancer and an alternative to radical surgery. Even if functional deficits are unavoidable in the treatment of locally advanced laryngeal carcinomas, larynx preservation is associated with a subjectively good QoL.
BACKGROUND AND PURPOSE: Transoral laser microsurgery (TLM) and adjuvant radiotherapy are an established therapy regimen for locally advanced laryngeal cancer at our institution. Aim of the present study was to assess value of quality of life (QoL) data with special regard to organ function under consideration of treatment efficacy in patients with locally advanced laryngeal cancer treated with larynx-preserving TLM and adjuvant radiotherapy. PATIENTS AND METHODS: From 1994 to 2006, 39 patients (ten UICC stage III, 29 UICC stage IVA/B) with locally advanced laryngeal carcinomas were treated with TLM and adjuvant radiotherapy. Data concerning treatment efficacy, QoL (using the VHI [Voice Handicap Index], the EORTC QLQ-C30 and QLQ-H&N35 questionnaires) and organ function (respiration, deglutition, voice quality) were obtained for ten patients still alive after long-term follow-up. Correlations were determined using the Spearman rank test. RESULTS: After a median follow-up of 80.8 months, the 5-year overall survival rate was 46.8% and the locoregional control rate 76.5%, respectively. The larynx preservation rate was 89.7% for all patients and 100% for patients still alive after follow-up. Despite some verifiable problems in respiration, speech and swallowing, patients showed a subjectively good QoL. CONCLUSION:TLM and adjuvant radiotherapy is a curative option for patients with locally advanced laryngeal cancer and an alternative to radical surgery. Even if functional deficits are unavoidable in the treatment of locally advanced laryngeal carcinomas, larynx preservation is associated with a subjectively good QoL.
Authors: J L Lefebvre; D Chevalier; B Luboinski; A Kirkpatrick; L Collette; T Sahmoud Journal: J Natl Cancer Inst Date: 1996-07-03 Impact factor: 13.506
Authors: R J Amdur; J T Parsons; W M Mendenhall; R R Million; S P Stringer; N J Cassisi Journal: Int J Radiat Oncol Biol Phys Date: 1989-01 Impact factor: 7.038
Authors: Olivier Pradier; Hans Christiansen; Heinz Schmidberger; Alexios Martin; Martin C Jäckel; Wolfgang Steiner; Petra Ambrosch; Elke Kahler; Clemens F Hess Journal: Int J Radiat Oncol Biol Phys Date: 2005-09-19 Impact factor: 7.038
Authors: L J Peters; H Goepfert; K K Ang; R M Byers; M H Maor; O Guillamondegui; W H Morrison; R S Weber; A S Garden; R A Frankenthaler Journal: Int J Radiat Oncol Biol Phys Date: 1993-04-30 Impact factor: 7.038
Authors: L Tupchong; C B Scott; P H Blitzer; V A Marcial; L D Lowry; J R Jacobs; J Stetz; L W Davis; J B Snow; R Chandler Journal: Int J Radiat Oncol Biol Phys Date: 1991-01 Impact factor: 7.038
Authors: Hendrik Andreas Wolff; Friedrich Ihler; Nina Zeller; Christian Welz; Klaus Jung; Martin Canis; Wolfgang Steiner Journal: Eur Arch Otorhinolaryngol Date: 2015-04-12 Impact factor: 2.503
Authors: Tomasz Rutkowski; A Wygoda; K Składowski; B Hejduk; R Rutkowski; B Lukaszczyk-Widel; M Hutnik; B Maciejewski Journal: Eur Arch Otorhinolaryngol Date: 2011-11-25 Impact factor: 2.503
Authors: D Dionysopoulos; K Pavlakis; V Kotoula; E Fountzilas; K Markou; I Karasmanis; N Angouridakis; A Nikolaou; K T Kalogeras; G Fountzilas Journal: Strahlenther Onkol Date: 2013-02-13 Impact factor: 3.621
Authors: H A Wolff; C R M Wolff; C F Hess; K Jung; S Sennhenn-Kirchner; M Hinterthaner; A Müller-Dornieden; W Körber; K Marten-Engelke; R Roedel; H Christiansen; C Engelke Journal: Strahlenther Onkol Date: 2013-07-12 Impact factor: 3.621